The FDA’s expectations around equitable access and representative enrollment in clinical research have moved from encouraged to operationally expected. With the FDA’s Enhancing Participation in Clinical Trials – Eligibility Criteria, Enrollment Practices, and Trial Designs final guidance (published December 15, 2025), Sponsors are now being told to reduce preventable barriers to clinical research opportunities and design trials that better reflect real-world patient populations.
At the same time, Diversity Action Plans (DAPs) – mandated under FDORA and tied to requirements in the FD&C Act – mean Sponsors must be prepared to document and execute enrollment and retention strategies in a measurable way, not just state good intentions.
The practical question becomes: how do you turn these expectations into a trial model that’s workable, compliant, and scalable?
One of the clearest answers is the thoughtful use of clinical trial home nursing and other off-site research nurse services within hybrid and decentralized designs.
Why the FDA Is Emphasizing Participation Barriers So Explicitly
For years, Sponsors have known that certain populations are routinely underrepresented. What’s shifted is how directly the FDA is naming the mechanics of exclusion – including visit schedules, location constraints, and the reliance on caregiver support.
In the December 2025 guidance, the FDA states:
“A trial requiring participants to make frequent visits to specific sites may result in added burden…especially older adults…disabled and cognitively impaired individuals…or participants who live far from research facilities, such as those in rural or remote locations.”
That’s not just commentary – it’s a signal about where Sponsors are expected to intervene: the operational design of participation.
DAPs Raise the Bar From “Try” to “Prove”
With mandatory DAPs, diversity becomes something Sponsors must plan for, implement, and monitor. FDA’s DAP draft guidance describes expectations around the form, content, and timing of these plans, and emphasizes that Sponsors should be able to demonstrate how they will reach enrollment goals and track progress during the study.
In practice, that means:
- You can’t rely on “site selection plus hope”
- You need defined enrollment goals, plus real tactics that make participation feasible
- You need monitoring and course-correction plans if enrollment starts to skew
Home-based models fit naturally here because they address barriers the FDA is calling out, in ways that can be described, measured, and repeated.
What Makes Home Nursing Model a Compliance-Aligned Participation Strategy?
Home nursing and off-site trial services aren’t just a “nice patient experience add-on.” They are a direct response to the burdens the FDA is highlighting travel frequency, accessibility constraints, and caregiver dependence.
The FDA even points to this type of approach when discussing ways to reduce participation burden, including the option to:
- Use electronic communication and digital tools instead of some site visits, and
- “Consider the use of mobile medical professionals, such as nurses and phlebotomists, to visit participants at their locations instead of requiring participants to visit distant clinical trial sites.”
So, the value isn’t theoretical. Home nursing models can be positioned as a risk-managed operational mechanism that supports representative enrollment while maintaining oversight and quality.
Home Nursing Activities That Reduce Site Burden While Maintaining Oversight
When implemented deliberately, off-site nursing can enable Sponsors to redesign participation without compromising data integrity or GCP expectations. Common activities that may be supported through home visits include:
- Sample collection (e.g., blood draws) and basic processing workflows
- Vital signs and safety assessments
- Patient-reported outcomes support (where appropriate)
- Training reinforcement (e.g., diaries, devices, adherence check-ins)
- Post-infusion follow-ups or protocol-driven safety visits (risk-based)
- Administration of IMP and adherence checks
These activities can be structured to reduce visit frequency at the main site while keeping investigator oversight intact through defined workflows, documentation, and escalation pathways.
The Diversity Impact: Who Benefits Most from Home-Based Options?
Clinical Trial home nursing models can reduce barriers for many groups the FDA explicitly references (and many that Sponsors see in practice), including:
- Patients in rural or remote locations
- Older adults or patients with mobility limitations
- Patients with disabilities who need accessibility accommodations
- Participants without reliable transport or caregiver support
- People balancing shift work, caregiving, or inconsistent schedules
And crucially, these are often the same groups that drive the hardest operational problems later: missed visits, protocol deviations, avoidable dropouts, and slower enrollment.
So, the impact isn’t only ethical or regulatory – it’s also pragmatic.
Making This “DAP-Ready”: How to Tie Home Nursing to Measurable Enrollment Strategy
If DAPs require Sponsors to show what they will do and how they’ll monitor it, home nursing becomes most powerful when connected to specific operational commitments, such as:
1) Participation burden reduction (by design)
- Identify the most travel-heavy visits and convert appropriate activities to home visits
- Build visit-window flexibility where clinically acceptable
2) Retention protection mechanisms
- Use home visits as “save points” for participants at risk of dropping (e.g., after hospitalization, caregiver loss, mobility changes)
3) Monitoring and accountability
- Track enrollment and retention by subgroup, and predefine triggers for deploying home visits more broadly when gaps emerge
These are concrete, reportable actions – the kind you can put into a DAP and then actually execute.
Key Takeaway and How WEP Clinical Can Support
The FDA is being increasingly direct and reinforcing the message that, if a trial design creates avoidable barriers to patient participation, Sponsors are expected to redesign the model.
Off- site research nursing models are one of the most practical ways to do that – because they operationalize flexibility, reduce participation burden, and support the measurable enrollment and retention strategies that DAP-driven trial planning now demands.
At WEP Clinical, we have the infrastructure to support clinical trial home nursing solutions in 60+ countries worldwide. We distinguish ourselves through an operating model designed to make home visits easier to deploy and easier to manage – with consistent processes, clear communication, and local delivery teams who understand what “good” looks like in a trial setting.
Whether you’re looking to reduce patient burden, strengthen retention, or operationalize elements of a Diversity Action Plan, we can help you design and deliver a home nursing approach that fits your protocol and your risk profile.
Learn more about how we can support your next clinical trial.